In this article LLY Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 22:24 22:24 Eli Lilly CEO: Our pill supply can 'reach the planet' News Videos The U.S. Food and Drug Administration approved Eli Lilly 's GLP-1 pill, the company said, a major milestone for the Indianapolis-based drugmaker and one that will test the market for new weight-loss medications. Lilly said the once-daily ...
In this article LLY Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 22:24 22:24 Eli Lilly CEO: Our pill supply can 'reach the planet' News Videos The U.S. Food and Drug Administration approved Eli Lilly 's GLP-1 pill, the company said, a major milestone for the Indianapolis-based drugmaker and one that will test the market for new weight-loss medications. Lilly said the once-daily pill, Foundayo, will start shipping from direct-to-consumer platform LillyDirect on Monday and will be available at pharmacies and on telehealth platforms "shortly after." People with insurance coverage could pay $25 a month with a coupon from Lilly, while people paying out of pocket could pay between $149 and $349, depending on the dose. The approval comes just a few months after Lilly submitted the drug to the FDA as part of a program that grants speedy reviews for drugs that are considered national priority interests. That means Lilly will introduce its Foundayo only about three months behind Novo Nordisk's Wegovy pill , setting the stage for the next battle between the rival drugmakers in the next frontier for GLP-1 drugs. "It's a big moment," Eli Lilly CEO Dave Ricks said in an interview with CNBC. "We've obviously been working in this category of medicines for a while with the first GLP-1 medication 20 years ago and improving ever since. Here is an option that's not more effective ... but it's more accessible, it's easier to fit into your daily routine." Lilly licensed the molecule, orforglipron, from Japanese drugmaker Chugai in 2018, paying just $50 million upfront for global rights to the drug. It doesn't produce as much weight loss as Lilly's best-selling shot Zepbound, which raises questions about how big the drug will become when millions of people seem content injecting themselves once a week. Eli Lilly Foundayo GLP-1 Weight loss pill. Courtesy: Eli Lilly Analysts estimate Foundayo sales will reach $14.79 billion by 2030, according to FactSet. That compares to ...
Tech giant Nvidia (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) both just reported blockbuster AI-driven quarters. Nvidia posted Q4 revenue of $68.13 billion, up 73.2% year-over-year, while Broadcom delivered Q1 FY2026 revenue of $19.31 billion, up 29.5% year-over-year. Both are winning the AI infrastructure buildout, but in very different ways. GPUs Dominate One. Custom Silicon Drives the Other. ... N...
Tech giant Nvidia (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) both just reported blockbuster AI-driven quarters. Nvidia posted Q4 revenue of $68.13 billion, up 73.2% year-over-year, while Broadcom delivered Q1 FY2026 revenue of $19.31 billion, up 29.5% year-over-year. Both are winning the AI infrastructure buildout, but in very different ways. GPUs Dominate One. Custom Silicon Drives the Other. ... Nvidia vs Broadcom: Which AI Stock Will Make You More Money
Antonio_Diaz/iStock via Getty Images On a personal level, I am not a fan of the for-profit education space. Having said that, I believe it is a fascinating industry to play in. The opportunities for attractive upside are definitely there. And with some companies, the growth rate is undeniably impressive. One good example of this can be seen by looking at Laureate Education ( LAUR ), a rather sizab...
Antonio_Diaz/iStock via Getty Images On a personal level, I am not a fan of the for-profit education space. Having said that, I believe it is a fascinating industry to play in. The opportunities for attractive upside are definitely there. And with some companies, the growth rate is undeniably impressive. One good example of this can be seen by looking at Laureate Education ( LAUR ), a rather sizable player with a market capitalization as of this writing of $5.05 billion. Over the last few years, management has really increased the size of the business on both the top and bottom lines. Moving forward, I expect this trend to continue as well. When you add on top of this how the stock is priced currently, a "Buy" rating makes all the sense in the world. Of course, this picture could change as new data comes in. And it just so happens that, on April 30, the management team at the company is expected to announce financial results for the first quarter of the company's 2026 fiscal year. We should expect continued expansion during this time. But if something unexpected comes out of the woodwork, my assessment could change. An interesting education provider Author - SEC EDGAR Data For those who have never heard of Laureate Education before, it's helpful to know that the company focuses on providing certain education-related services from institutions that it has throughout Mexico and Peru. Management collectively refers to these as its Laureate International Universities network. At the end of the 2025 fiscal year , the company had five different institutions that boasted more than 50 campuses. Combined, they had about 497,700 students. And those students focus on a wide array of educational paths. Through these multi-year degree programs, they focus on fields such as medicine and health sciences, engineering and information technology, and business and management. These are the three largest disciplines that the company has, accounting for around 70% of its enrollments. Ot...
greenleaf123 A court in Belgium ordered Poland and Romania to accept the delivery of €1.9B ($2.2B) worth of COVID-19 vaccines developed by Pfizer ( PFE ) and BioNTech ( BNTX ) in a dispute over a pandemic-era procurement deal. The ruling is related to a case brought by Pfizer ( PFE ) and BioNTech ( BNTX ) in 2023, which accused the countries of failing to honor multi-billion-dollar vaccine procure...
greenleaf123 A court in Belgium ordered Poland and Romania to accept the delivery of €1.9B ($2.2B) worth of COVID-19 vaccines developed by Pfizer ( PFE ) and BioNTech ( BNTX ) in a dispute over a pandemic-era procurement deal. The ruling is related to a case brought by Pfizer ( PFE ) and BioNTech ( BNTX ) in 2023, which accused the countries of failing to honor multi-billion-dollar vaccine procurement deals signed at the height of the pandemic. Poland and Romania, which had agreed to buy COVID vaccine doses from Pfizer ( PFE ) and BioNTech ( BNTX ) as part of a joint procurement deal with the European Commission and vaccine makers in 2021, had refused to honor commitments, citing the shift in the pandemic and other reasons. The Brussels Court of First Instance on Wednesday ordered Poland and Romania to accept the delivery of €1.3B and €600M worth of Pfizer ( PFE )/BioNTech ( BNTX ) COVID-19 vaccine doses, respectively. More on Pfizer, BioNTech Pfizer: Why Wall Street Habitually Overestimates Target Price Why Pfizer Remains A Strong Buy In 2026 Pfizer: Undervalued High-Yield Giant With A Pipeline Built For The Next Decade Pfizer is said to close South San Francisco research site FDA ready to allow compounding pharmacies to make injectable peptides - report
The Kohn Solution For An Uncertain Fed Via RealInvestmentAdvice.com, Dario Perkins of TS Lombard wrote a piece titled “ How to Respond to Oil Shocks .” His analysis draws on the Fed’s history to address how it should respond to today’s oil shock. While researching Fed transcripts from the 1990 Gulf War, he discovered a proposal by Don Kohn, senior Fed staffer, that offers a solution to the central...
The Kohn Solution For An Uncertain Fed Via RealInvestmentAdvice.com, Dario Perkins of TS Lombard wrote a piece titled “ How to Respond to Oil Shocks .” His analysis draws on the Fed’s history to address how it should respond to today’s oil shock. While researching Fed transcripts from the 1990 Gulf War, he discovered a proposal by Don Kohn, senior Fed staffer, that offers a solution to the central bank’s oil shock problem: nominal GDP targeting. Kohn’s logic is straightforward and makes sense in the current environment where the Fed is contemplating monetary policy as oil prices spike, simultaneously boosting inflation and reducing economic growth. Per Kohn, if those two forces balance out, the Fed should hold rates steady. But if one dominates, the Fed should respond: “ hike if nominal GDP growth rises ” and “ cut if nominal GDP growth falls .” In other words, a demand shock calls for higher rates, while a supply-side shock calls for lower rates. Historically, as he shares in the table below, nominal GDP almost always falls after a supply-driven oil shock. Today’s spike, driven by the Iranian conflict and “ the Iranian weaponization of the Strait of Hormuz ,” is unambiguously a supply shock. By the Kohn framework, the Fed should be cutting the Fed Funds rate, not considering hiking it. The current counterargument is the high-inflation era of the 1970s, when central banks were allegedly too dovish on inflation and allowed inflation expectations to spiral out of control. Perkins dismisses this comparison directly. To wit: The 1973-74 recession “was one of the worst in history” and “in terms of its impact on unemployment, it was only slightly better than the GFC.” Importantly, he notes that the 1970s featured widespread union membership and inflation-indexed wage contracts that caused wages to “ accelerate even as the economy sank. ” That wage-price spiral is nonexistent today. Thus, the inflationary danger of easing into an oil shock is considerably lower than the po...
J Studios/DigitalVision via Getty Images Achieve Life Sciences (NASDAQ: ACHV ) is a clinical stage biopharmaceutical firm devoted to treating nicotine dependency. Their main product, dubbed cytisinicline, is a plant-derived alkaloid with the ability to bind the same receptors as nicotine. The drug is currently under review by the FDA, with a PDUFA set for 20 June 2026. Recently , the stock experie...
J Studios/DigitalVision via Getty Images Achieve Life Sciences (NASDAQ: ACHV ) is a clinical stage biopharmaceutical firm devoted to treating nicotine dependency. Their main product, dubbed cytisinicline, is a plant-derived alkaloid with the ability to bind the same receptors as nicotine. The drug is currently under review by the FDA, with a PDUFA set for 20 June 2026. Recently , the stock experienced a sell-off following the last earnings call: the FDA pointed out manufacturing issues, thus decreasing the probability of approval in June. However, we believe the sell-off could be an opportunity to enter a high-risk, high-reward position and therefore rate it a Buy for risk-taking investors. We will first discuss the clinical part, reviewing the data available on Cytisinicline, and then the business part, deciphering the competitive advantages and a possible valuation of the company. Summary of Cytisinicline’s clinical trials In this section, we will detail the clinical data available for their product. Cytisinicline is designed to help smoking cessation in adult patients. Cytisinicline has been investigated in 4 clinical trials and one open-label (OL) safety trial. Their first clinical trial was a Phase 1 trial , evaluating the safety of the compound. The study was a double-blind, placebo-controlled, single-ascending-dose trial. 54 patients received Cytisinicline, and 18 received a placebo. The drug was proven safe, with nausea being the most common side effect, occurring in 19% of the participants. The company then moved on to a Phase 2b trial, dubbed the ORCA-1 trial, aiming to determine the optimal regimen for drug efficacy and tolerability. Here, 254 patients received either Cytisinicline 1.5mg or 3mg or a placebo in addition to behavioral support for 25 days. Patients were adult smokers of over 10 cigarettes daily. Interestingly, all Cytisinicline groups significantly overperformed placebo. Also, a slight dose-dependent efficacy was observed as patients receivi...
Joyce gave birth in November and returned to pitch in March Bristol flanker hopes to be role model for next generation Alisha Joyce returned to the rugby pitch in March just 123 days after giving birth and a week later was named in Wales’s squad for the Women’s Six Nations. The 28-year-old says she was “shocked” to get the call-up after welcoming son Ralphie in November but adds it’s “cool” to be ...
Joyce gave birth in November and returned to pitch in March Bristol flanker hopes to be role model for next generation Alisha Joyce returned to the rugby pitch in March just 123 days after giving birth and a week later was named in Wales’s squad for the Women’s Six Nations. The 28-year-old says she was “shocked” to get the call-up after welcoming son Ralphie in November but adds it’s “cool” to be a role model for the next generation of players. Joyce was the first Wales player to use the governing body’s new performance maternity programme. The back-row, who shares Ralphie with her wife and teammate Jasmine Joyce, has played only 30 minutes of rugby since returning last month in a game for Brython Thunder where she came off the bench. Continue reading...
Jovanmandic/iStock via Getty Images On March 30th, Sysco Corporation ( SYY ) announced their plan to acquire Restaurant Depot by the third quarter of their 2027 fiscal year. After this announcement, the company saw a huge drop in their share price (15%). I will go over what this acquisition means for Sysco shareholders and how I expect them to move forward. In light of this news, I am rating Sysco...
Jovanmandic/iStock via Getty Images On March 30th, Sysco Corporation ( SYY ) announced their plan to acquire Restaurant Depot by the third quarter of their 2027 fiscal year. After this announcement, the company saw a huge drop in their share price (15%). I will go over what this acquisition means for Sysco shareholders and how I expect them to move forward. In light of this news, I am rating Sysco as a Buy because, with a long-term view, the step management just took does make very good sense, but there are some negative points to cover. Restaurant Depot is a chain of tangible storage warehouses (structured very similarly to Costco, but only registered businesses have access to shop there). The company is the biggest cash-and-carry food wholesaler in the US, with 130 owned warehouses/stores spread all across the US. The deal will cost Sysco $29 billion, 65% of their previous market capitalization, before the share price tumbled ($39 billion). After trading hours, the market capitalization of Sysco is only $34 billion. From the current standpoint, Sysco is paying 83% of their market cap for this acquisition. Acquisition Details This is not pleasant news for Sysco shareholders. Especially when the company already has $15 billion in long-term liabilities and $25 billion in total liabilities. Since the latest earnings, Sysco has only about $1.2 billion of cash on their hands. As management said , the rest ($28 billion) will come from two directions. $21 billion will come from new and hybrid debt, and the rest from 91.5 million shares of Sysco. Compelling Transaction (sysco.com) Since 2016 , Sysco has bought back roughly 17.5% of their outstanding shares (85 million shares). By giving Restaurant Depot shareholders 91.5 million shares, they are looking at an increase of 18.8% to the shares outstanding. This will bring them back to 2015-2016 levels, 10 years back. This is going to heavily dilute the current shareholder value (about 18%), meaning that the market reaction to...
YieldMax HIMS Option Income Strategy ETF ( HIYY ) announces weekly distribution of $0.2192, 2.05% higher from the prior week's distribution of $0.2147. The annual distribution rate is 80.53%, with an SEC yield of 7.43%. The return of capital is 19.37%. Payable April 6; for shareholders of record April 2; ex-div April 2.Source: Press Release More on YieldMax HIMS Option Income Strategy ETF Dividend...
YieldMax HIMS Option Income Strategy ETF ( HIYY ) announces weekly distribution of $0.2192, 2.05% higher from the prior week's distribution of $0.2147. The annual distribution rate is 80.53%, with an SEC yield of 7.43%. The return of capital is 19.37%. Payable April 6; for shareholders of record April 2; ex-div April 2.Source: Press Release More on YieldMax HIMS Option Income Strategy ETF Dividend scorecard for YieldMax HIMS Option Income Strategy ETF
In speech in Washington DC, Harry spoke of ‘harrowing stories’ of how time on tech giants’ platforms led to ‘grave and irreversible harm’ The Duke of Sussex has welcomed two landmark lawsuits against major tech companies, declaring: “Finally, some truth and accountability has arrived.” In a speech in Washington DC to the International Association of Privacy Professionals (IAPP) global summit on pr...
In speech in Washington DC, Harry spoke of ‘harrowing stories’ of how time on tech giants’ platforms led to ‘grave and irreversible harm’ The Duke of Sussex has welcomed two landmark lawsuits against major tech companies, declaring: “Finally, some truth and accountability has arrived.” In a speech in Washington DC to the International Association of Privacy Professionals (IAPP) global summit on privacy, AI governance and cybersecurity law, Prince Harry said he had done a “deep dive into the tech-fuelled world in which my children – all our children – are growing up in”. Continue reading...